Discovery of genes that modulate flavivirus replication in an interferon-dependent manner

Sarah Lesage[1,2]*, Maxime Chazal[1]*, Guillaume Beauclair[1,3], Damien Batalie[4], Elodie Couderc[1,5], Aurianne Lescure[6], Elaine Del Nery[6], Frédéric Tangy[7], Annette Martin[4], Nicolas Manel[8#] and Nolwenn Jouvenet[1#]

* These authors contributed equally

[#] corresponding authors

[1] Institut Pasteur, Virus Sensing and Signaling Unit, UMR3569 CNRS, Paris, France

[2] Université de Paris, Paris, France

[3] Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France

[4] Institut Pasteur, Molecular Genetics of RNA Viruses Unit, UMR3569 CNRS, Université de Paris, Paris, France

[5] Institut Pasteur, Insect-Virus Interactions Unit, Department of Virology, UMR2000 CNRS, Paris, France

[6] Institut Curie, PSL Research University, Department of Translational Research-Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France

[7] Institut Pasteur, Viral Genomics and Vaccination Unit, UMR3569 CNRS, Paris, France

[8] Institut Curie, PSL Research University, INSERM U932, Paris, France.

Abstract

Establishment of the interferon (IFN)-mediated antiviral state provides a crucial initial line of defense against viral infection. Numerous genes that contribute to this antiviral state remain to be identified. Using a loss-of-function strategy, we screened an original library of 1156 siRNAs targeting 386 individual curated human genes in stimulated microglial cells infected with Zika virus (ZIKV), an emerging RNA virus that belongs to the flavivirus genus. The screen recovered twenty-one potential host proteins that modulate ZIKV replication in an IFN-dependent manner, including the previously known IFITM3 and LY6E. Further characterization contributed to delineate the spectrum of action of these genes towards other pathogenic RNA viruses, including Hepatitis C virus and SARS-CoV-2. Our data revealed that APOL3 acts as a proviral factor for ZIKV and several other related and unrelated RNA viruses. In addition, we showed that MTA2, a chromatin remodeling factor, possesses potent flavivirus-specific antiviral functions. Our work identified previously unrecognized genes that modulate the replication of RNA viruses in an IFN-dependent way, opening new perspectives to target weakness points in the life cycle of these viruses.

Introduction

Viruses are high on the list of global public health concerns, as illustrated by recent epidemics caused by Ebola, Zika (ZIKV) and Nipah viruses, as well as by the ongoing SARS-CoV-2 pandemic. The vast majority of these emerging RNA viruses have zoonotic origins and have recently crossed host species barrier [1]. In order to establish itself in a host species, one of the first and most restrictive barriers that a virus needs to overcome is the antiviral innate immune system. This response has evolved to rapidly control viral replication and limit virus spread *via* detection of viral nucleic acids by pathogen recognition receptors (PRRs) [2]. These PRRs can be membrane-associated, such as Toll-like receptor (TLRs), or cytosolic, such as retinoic acid inducible gene I (RIG-I)-like receptor (RLRs). Upon binding to viral nucleic acids, these PRRs interact with adaptor proteins and recruit signaling complexes. These events lead to the expression of type I interferons (IFNs). Secreted IFNs will then bind to their heterodimeric receptor (IFNAR1/IFNAR2) and activate the canonical JAK/STAT pathway in infected and surrounding cells. This activation triggers the assembly of the interferon-stimulated gene 3 (ISGF3) complex (composed of STAT1, STAT2 and IRF-9 proteins), which subsequently induces the expression of up to approximately 2000 IFN-stimulated genes (ISGs) [3,4], effectively establishing the antiviral state. ISGs comprise a core of genes that are induced at high levels essentially in all cell types, as well as cell-type specific genes that are the result of transcriptome remodeling [5,6], highlighting the importance of studying ISGs in relevant cell types. Some of these ISGs have been well characterized. They directly block the viral life cycle by targeting specific stages of virus replication, including entry into host cells, protein translation, replication or assembly of new viral particles [3,7]. Some ISGs are specific to a virus or a viral family, while others are broad-spectrum. They can also be negative or positive regulators of IFN signaling and thus facilitate, or not, the return to cellular homeostasis. However, the contribution of most ISGs to the antiviral state remains poorly understood.

Over the last decades, flaviviruses have provided some of the most important examples of emerging or resurging diseases, including ZIKV, dengue virus (DENV), Yellow fever virus (YFV) and West Nile virus (WNV) [8]. These flaviviruses are arthropod-borne viruses transmitted to vertebrate hosts by mosquitoes. They cause a spectrum of potentially severe diseases including hepatitis, vascular shock syndrome, encephalitis, acute flaccid paralysis, congenital abnormalities and fetal death [8]. They are now globally distributed and infect up to 400 million people annually. Lesser-known flaviviruses are beginning to emerge in different parts of the world, as illustrated by the recent incursion of Usutu virus (USUV) in the Mediterranean basin [9].

ZIKV was isolated in 1947 in a macaque from the Zika Forest in Uganda [10]. For decades, it remained in Africa and Asia where it sparked local epidemics characterized by a mild self-limiting disease in humans. In recent years, Asian lineage viruses have emerged as a global public health threat with widespread epidemics in the Pacific Islands and Americas, where over 35 countries have reported local transmission in 2016. An estimated 1 million individuals were affected by ZIKV in Brazil in 2015-16. Infection by ZIKV has been linked to several neurological disorders, including Guillain-Barré syndrome (GBS),

meningoencephalitis, myelitis and congenital microcephaly, fetal demise and abortion [10]. Children exposed to ZIKV in utero may present neurocognitive deficits, regardless of head size at birth. ZIKV infection is now identified as a sexually-transmitted illness as well [11]. As all flaviviruses, ZIKV is an enveloped virus containing a positive-stranded RNA genome of ~11 kb. Upon viral entry, the viral genome is released and translated by the host cell machinery into a large polyprotein precursor. The latter is processed by host and viral proteases into three structural proteins, including C (core), prM (precursor of the M protein) and E (envelope) glycoproteins, and seven non-structural proteins (NS) called NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 [8]. The structural proteins constitute the viral particle, while NS proteins coordinate RNA replication, viral assembly and modulate innate immune responses.

The importance of IFN signaling in mediating host restriction of ZIKV is illustrated by the severe pathogenicity in IFNAR1-/- and STAT2-/- but not in immunocompetent mice [12–14]. Moreover, the Zika strain that is responsible for the recent epidemics has accumulated mutations that increase neurovirulence via the ability to evade the immune response [15]. Microglial cells, which are the resident macrophages of the brain, represent ZIKV targets and potential reservoirs for viral persistence [16]. Moreover, they may play a role in ZIKV transmission from mother to fetal brain [17] and affect the proliferation and differentiation of neuronal progenitor cells [18]. In order to comprehend the molecular bases behind the efficacy of the IFN response to ZIKV replication, we set up a high throughput assay to identify genes that are modulating viral replication in human microglial cells (HMC3) stimulated with IFN.

Results

A loss of function screen identified genes modulating ZIKV replication in IFN-stimulated human microglial cells

We first performed pilot experiments to determine the feasibility of conducting large-scale loss-of-function studies to identify novel genes regulating ZIKV replication in stimulated HMC3 cells. Five hundreds cells were seeded in 384-well microplates on day 1, transfected with individual siRNA 6 hours later, treated with IFNα2 at day 2, infected with ZIKV at day 3 and fixed 24 hours later (Fig. 1A). Percentages of infected cells were determined by confocal analysis by measuring the number of cells expressing the viral E protein, using the pan-flavivirus anti-E antibody 4G2 (Fig. 1A). Nuclei were identified with DAPI staining for imaging and segmentation purposes. We optimized IFNα2 concentration and viral multiplicity of infection (MOI) to obtain a significant decrease of E-positive cells upon IFNα2-treatment (Fig. S1A). We used siRNAs targeting IFNAR1, which are expected to neutralize IFN signaling, as positive controls (Fig. S1A). siRNAs against IFITM3, an ISG known to potently inhibit ZIKV replication in several human cell lines and primary fibroblasts [19,20], were used as additional positive controls (Fig. S1A). Negative controls were non-targeting siRNAs. As expected,

110 in the presence of siRNAs targeting IFNAR1, IFN signaling was neutralized and the level of infection
111 was almost rescued to the level of non-treated cells (Fig. S1A). In cells silenced for IFITM3 expression,
112 the number of infected cells was partly restored to the level of non-treated cells (Fig. S1A). Such partial
113 rescue was expected since the antiviral state requires the concerted action of numerous ISGs [21]. These
114 data also revealed that IFITM3 is a potent anti-ZIKV ISG in microglial cells.

115 We scaled up the experiment by screening an arrayed library containing 1158 siRNAs targeting 386
116 human genes (Table S1). These genes were selected based on a gene signature defined by clustering and
117 correlation of expression with MX1, a well-described ISG, in a dataset of gene expression in primary
118 human $CD4^+$ T cells (Cerboni et al., in preparation). 36% of the identified genes overlapped with
119 previous ISG libraries [21,22], ensuring that the screen would be simultaneously capable of identifying
120 expected positive hits and find new genes of interest. To overcome potential off-target effect and a
121 limited efficacy of transcript knockdown, each gene was targeted by 3 different siRNAs. Numerous
122 siRNAs targeting IFNAR1 and IFNAR2 were used as positive controls. Negative controls were non-
123 targeting siRNAs. Transfection efficiency was evaluated using siRNAs against KIF11, a protein
124 essential for cell survival [23]. The same experimental protocol than in small-scale experiments was
125 applied (Fig. 1A). Three images were acquired per condition with an INCell2200 automated wide-field
126 system. The mean cell count and the percentages of infected cells were extracted from quantification.
127 The screen was performed in duplicate.

128 For quality control purposes, we first compared the number of cells in each well in the 2 replicates.
129 We observed an expected distribution of the number of cells in 3 fields with a median close to 1000
130 cells per well for the two replicates (Fig. S1B). The number of cells per condition was slightly higher in
131 the first replicate than in the second one. However, the R^2 coefficient of determination of the linear
132 regression was close to 0.7 (Fig. S1C), indicating that the reproducibility of the experiment was correct.
133 As expected [23], siRNAs against KIF11 were lethal, validating the transfection protocol (Fig. S1B, C).
134 The 2 screens were first analyzed by taking into consideration the intensity of the E signal per cell. The
135 number of cells expressing the viral protein E distributed as predicted, with a median close to 15% for
136 the 2 screens (Fig. S1D). As expected from pilot experiments (Fig. S1A), siRNAs targeting IFNAR-1
137 and -2 rescued ZIKV replication in IFN-treated cells (Fig. S1D, E). The reproducibility of the infection
138 status of the cells between the 2 screens, with a R^2 greater than 0.8, was satisfactory (Fig. S1E). The
139 data were then analysis using a second approach that identified infected cells based on the E expression
140 independently of the intensity of the signal. The 2 methods identified similar number of infected cells
141 (Fig. S1F). Results were expressed as robust Z-scores for each siRNA (Fig. 1B, C). Genes were defined
142 as hits when at least two over three of their robust Z scores had an absolute value superior to 2 in the
143 two replicates, in at least one of the analysis. The screen identified 9 antiviral genes and 12 proviral ones
144 (Fig. 1D). Some hits were previously described as modulators of ZIKV replication, such as IFITM3
145 [19,20] and LY6E [24], thus validating our loss-of-function screening approach. These twenty-one hits
146 were selected for further validation.

147 IFNα2-treated HMC3 cells were transfected with pool of 3 siRNAs against each candidate, and not
148 by individual ones as in the primary screening. Twenty-four hours post-ZIKV infection, intracellular
149 viral RNA production was quantified by RT-qPCR and the number of cells positive for the viral protein
150 E was assessed by flow cytometry analysis. The same samples were used to assess the efficacy of the
151 siRNAs. RT-qPCR analyses revealed that 15 out of the 21 siRNA pools were reducing the expression
152 of their respective targets in IFN-treated cells (Fig. S1G). mRNAs levels of C1R, XCL1, GBP3, NADK,
153 C22orf39 and RUBCN were below the detection limit in IFNα2-treated HMC3 (Fig. S1G). These genes
154 were thus excluded from further anaysis. Reduced expression of IRF9, IFITM3, MTA2 and GPD2
155 significantly enhanced both viral RNA yield and the number of infected cells as compared to IFNα2-
156 treated cells transfected with control siRNAs (Fig. 1E and F). Both IRF9, which belongs to the ISGF3
157 complex [25], and IFITM3 [26] are well-known broadly-acting IFN effectors. The activities of MTA2
158 have, so far, not been linked to antiviral immunity. MTA2 is a component of the nucleosome remodeling
159 deacetylase NuRD complex, which exhibits ATP-dependent chromatin remodeling activity in addition
160 to histone deacetylase activity [27]. Ten times more viral RNA copies were recovered in cells silenced
161 for MTA2 expression than in control cells (Fig. 1E) and four times more cells were positive for the viral
162 E protein (Fig. 1F). These effects were comparable to the ones induced by IFNAR1 silencing (Fig. 1E
163 and F). Transfection with siRNA against the other 3 antiviral candidates (PXK, NMI and IFI16) had no
164 significant effect on ZIKV replication in these assays (Fig. 1E and 1F), suggesting that they may be
165 false positive candidates. Reducing the expression of LY6E, ISG15 and APOL3 significantly decreased
166 both viral RNA production and the number of cells positive for the E protein (Fig. 1G and 1H), validating
167 the pro-viral activities of these 3 candidates. The pro-viral function of USP18 and NAPA were also
168 validated since reducing their expression led to a significant reduction of the number of infected cells
169 as compared to control cells (Fig. 1H). Reduced expression of ISG20 or CCND3 had no significant
170 effect on ZIKV replication (Fig. 1G and 1H). IRF2, which was identified as a pro-viral hit by the screen,
171 behaved like an antiviral gene in the validation experiments (Fig. 1G). Together, these experiments
172 validated the antiviral function of IRF9, IFITM3, MTA2 and GPD2 and the pro-viral function of LY6E,
173 USP18, ISG15, APOL3 and NAPA in IFNα2-treated HMC3 cells infected with ZIKV.
174
175 **Effect of a selection of candidate genes on HCV and SARS-CoV-2 replication**
176 We next explored the ability of 10 candidate genes (IRF9, IFITM3, MTA2, GPD2, LY6E, USP18,
177 ISG15, APOL3, GBP3 and NAPA) to modulate the replication of two other pathogenic RNA viruses:
178 Hepatitis C virus (HCV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which
179 are, respectively, related and unrelated to ZIKV. HCV, which is a member of the Hepacivirus genus
180 within the *Flaviviridae* family, has a tropism for hepatocytes. SARS-CoV-2 belongs to the
181 *Coronaviridae* family and has a tropism for pneumocytes and enterocytes.

182 HCV infections were conducted in hepatoma Huh-7.5 cells, which support well viral replication [28].
183 Huh-7.5 cells are unable to induce IFN expression since they express an inactive form of RIG-I [29] but
184 they possess an intact JAK/STAT pathway and do thus respond to IFN treatment [30]. RT-qPCR
185 analyses revealed that 8 out 10 siRNA pools efficiently reduced the expression of their respective targets
186 in stimulated Huh-7.5 cells (Fig. S2A). Since LY6E and APOL3 mRNA levels were under the limit of
187 detection of the assays in IFNα2-treated Huh-7.5 cells (Fig. S2A), they were excluded from further
188 analysis. As expected, reduced expression of IFNAR and IRF9 significantly enhanced HCV RNA yield
189 and the production of infectious particles in IFNα2-treated Huh-7.5 cells, as compared to control cells
190 (Fig. 2A, B). Reduced expression of IFITM3, MTA2 or GPD2, which significantly enhanced ZIKV
191 replication in HCM3 cells (Fig. 1E, F), did not affect HCV RNA production (Fig. 2A). However,
192 surprisingly, their reduced expression triggered a significant decrease in the release of infectious HCV
193 particles as compared to control cells (Fig. 2B). This suggests that they might favor a late stage of HCV
194 replication cycle. RT-qPCR analysis and titration assays identified USP18 and ISG15 as pro-HCV
195 factors in IFNα2-treated Huh-7.5 cells (Fig. 2C, D), validating previous results [31–34]. Of note, HCV
196 RNA production and infectious particle release were significantly increased in cells with reduced NAPA
197 levels (Fig. 2C, D), suggesting that NAPA may exert an antiviral effect on HCV, while it was not the
198 case for ZIKV (Fig. 1G, H).
199 SARS-CoV-2 replication was assessed in A549 alveolar epithelial cells expressing the viral receptor
200 ACE2 (A549-ACE2) by RT-qPCR and flow cytometry analysis using an antibody against the viral
201 protein Spike (S). Of note, silencing GBP3 in A549-ACE2 cells triggered cell death. RT-qPCR analyses
202 showed that all siRNA pools were reducing the expression of their respective targets in stimulated A549-
203 ACE2 cells (Fig. S2B). These analyses revealed the ability of IRF9 to act as an anti-SARS-CoV-2 gene
204 (Fig. 2E, F). Unexpectedly, GPD2 and IFITM3, which we identified as genes possessing anti-ZIKV
205 activities (Fig. 1), tended to behave like pro-viral genes in the context of SARS-CoV-2 infection (Fig.
206 2E and 2F). Viral RNA yields decreased significantly in cells silenced for USP18, ISG15 and NAPA
207 expression, as compared to cells transfected with control siRNAs (Fig. 2G), suggesting that these 3
208 genes promote viral replication in stimulated A549-ACE2 cells. By contrast to what we observed in
209 ZIKV infected cells (Fig. 1G, H), LY6E seemed to restrict SARS-CoV-2 (Fig. 2H). These results are in
210 accordance with a recent report [35]. Reducing MTA2 or APOL3 expression did not affect SARS-CoV-
211 2 replication.
212 These results suggest that some genes are broadly-acting IFN effectors, such as IRF9 and ISG15.
213 Other genes appeared to have evolve modulatory function toward a specific viral family or genus, such
214 as APOL3 and MTA2. Finally, some genes, including LY6E, IFITM3 and GPD2, exhibited opposite
215 modulatory functions towards different viral species.
216
217 **ZIKV, DENV-2, WNV, VSV and MeV, but not MVA, require the expression of APOL3 for**
218 **optimal replication in IFN-treated cells**

219 LY6E, ISG15 and APOL3 exhibited significant pro-ZIKV activities in stimulated cells, as measured
220 by cell-associated viral RNA levels (Fig. 1G) and percentage of E-positive cells (Fig. 1H). Among these
221 3 genes, APOL3 is the least described and was thus selected for further characterization. APOL3 is one
222 of the 6 members of the apolipoprotein L gene family. Apolipoproteins are typically associated with the
223 transport of lipids in the organism and were originally described as members of the high-density
224 lipoprotein family, which are involved in cholesterol transport [36]. In human cells, the expression of
225 the 6 members of the APOL gene family are up-regulated by multiple pro-inflammatory signaling
226 molecules, including IFNs and TNFα [36,37]. These regulations suggest a link between APOL proteins
227 and the innate immune system. siRNA targeting APOL2, APOL3, APOL4, APOL5 and APOL6 were
228 present in our library (Table S1). Among these 5 APOLs, only APOL3 was identified as a facilitator of
229 ZIKV infection by our screen (Fig. 1). We decided to test the ability of APOL1 to modulate ZIKV
230 replication since it was previously identified in a high-throughput overexpression screen as an ISG able
231 to increase YFV infection in *STAT1*$^{-/-}$ fibroblasts and Huh-7cells [21].
232 Analysis of mRNA levels of APOL1 and APOL3 revealed that the genes were upregulated by
233 IFNα2 treatment in HMC3 cells (Fig. 3A). Both genes thus qualify as genuine ISGs in these cells. The
234 implication of APOL1 and APOL3 in ZIKV replication was investigated using loss-of-function
235 approaches. siRNA-silencing reduced the levels of APOL1 and APOL3 mRNAs by ~80% and ~85%,
236 respectively, when compared to cells expressing scrambled control siRNAs (Fig. 3B). USP18, which is
237 known to negatively regulates the JAK-STAT pathway, and, as such, is a broad-spectrum pro-viral
238 factor [38], was identified during our screen as a pro-ZIKV candidate in HMC3 cells (Fig. 1D). Since
239 its pro-ZIKV function was validated in our system (Fig. 1H), siRNAs specific for USP18 were used as
240 positive controls. siRNA-silencing reduced the abundance of USP18 mRNAs by ~80% when compared
241 to cells expressing control siRNAs (Fig. 3B). Viral replication was assessed by flow cytometry by
242 measuring the number of cells positive for the viral protein E in cells silenced for APOL1, APOL3 or
243 USP18, treated or not with IFNα2. Since ZIKV is sensitive to IFNα2-treatment (Fig. S1A), higher MOIs
244 were used in IFNα2-treated cells than in untreated ones to compensate for its antiviral effects. As
245 expected (Fig. 1H), reduced expression of USP18 significantly decreased the number of IFN-treated
246 cells positive for the viral protein E, as compared to cells transfected with control siRNAs (Fig. 3C).
247 Extinction of APOL1 and APOL3 resulted in a modest, but reproducible, decrease in the number of E-
248 positive HMC3 cells pre-treated with IFNα2 (Fig. 3C). A pro-viral effect of APOL1 was also observed
249 in unstimulated cells (Fig. 3C). The efficacy of the siRNAs against APOL1 and USP18 were further
250 validated by Western Blot analysis using specific antibodies (Fig. 3D). APOL3 levels in cell lysates
251 could not be assessed due to the lack of available antibodies. Levels of expression of the viral proteins
252 NS5 and E were slightly decreased in IFNα2-cells expressing reduced levels of APOL1 or APOL3,
253 compared to control cells (Fig 3D). Together, these results suggest that ZIKV requires the expression of
254 APOL1 and APOL3 for optimal replication in HMC3 cells. By contrast to APOL1, the pro-viral action

255 of APOL3 was dependent on IFNα2-treatment.

256 To ensure that the APOL1- and APOL3-mediated modulation of viral replication was not restricted
257 to HMC3 cells, silencing experiments were performed in ZIKV-infected human podocytes treated or
258 not with IFNα2. Podocytes are physiologically relevant for ZIKV infection since viral RNA was
259 detected in kidneys of infected patients [39]. Assessing the mRNA abundance of APOL1 and APOL3
260 by RT-qPCR analysis of cells treated or not with IFNα2 revealed that both genes qualify as ISGs in
261 podocytes (Fig. 3E). siRNA-mediated silencing of APOL1, APOL3 and USP18 was efficient in
262 podocytes (Fig. 3F). Reduced expression of APOL1 or APOL3 resulted in a significant decrease of the
263 percentage of infected cells in IFNα2-treated podocytes, but not in unstimulated cells (Fig. 3G). Western
264 blot analysis performed in IFNα2-treated podocytes revealed that cells expressing little APOL1/3 were
265 producing less viral proteins than controls cells (Fig. 3H), confirming the pro-ZIKV activity of the two
266 APOLs. These data revealed that APOL3 and APOL1 facilitate the replication of ZIKV in podocytes
267 treated with IFNα2.

268 We tested whether APOL1 and APOL3 were active against DENV-2 or WNV, which are mosquito-
269 borne flaviviruses closely related to ZIKV. HMC3 cells were treated or not with IFNα2 and the MOIs
270 were adapted to the IFNα2 treatment. Flow cytometry analysis using anti-E antibodies revealed that
271 both DENV-2 and WNV replication were significantly decreased in IFNα2-treated cells silenced for
272 APOL1 or APOL3 expression (Fig. 3I). Reducing APOL1 and APOL3 expression in non-treated cells
273 also significantly reduced WNV replication (Fig. 3I). Thus, APOL1/3 may well have flavivirus genus-
274 specific proviral activities since they seems to contribute to ZIKV, WNV and DENV replication (Fig.
275 3C, D, G, H and I) but not to SARS-CoV-2 replication (Fig. 2G, H). To further delineate the spectrum
276 of action of these two genes towards other viruses, we tested the effect of APOL1/3 silencing on the
277 replication of Vesicular Stomatitis virus (VSV) and Measles virus (MeV), which are negative-strand
278 RNA viruses belonging to the *Rhabdoviridae* and *Paramyxoviridae* families, respectively. Experiments
279 were performed with a MeV strain modified to express GFP [40]. We also included in the analysis
280 Modified Vaccinia Ankara virus (MVA), a DNA virus belonging to the *poxviridae* family, that was
281 engineered to express GFP (MVA-GFP). Flow cytometry analysis using an antibody against the viral
282 protein G revealed that VSV was highly dependent on APOL1 and APOL3 expression for efficient
283 replication in IFNα2-treated HMC3 cells (Fig. 3I). Optimal replication of MeV-GFP in stimulated
284 HMC3 cells also required APOL1 and APOL3 expression (Fig. 3I). APOL1 proviral activity was also
285 observed in unstimulated cells (Fig. 3I). By contrast, MVA-GFP replication was not affected by reduced
286 expression of either APOL1 or APOL3 (Fig. 3I).

287 Together, these experiments suggest that APOL1 and APOL3 could favor a replication process
288 shared by ZIKV, DENV-2, WNV, VSV and MeV. Unlike APOL1 in HMC3 cells, APOL3 pro-viral
289 activities were dependent on IFN-treatment.

290

291 **APOL1 and APOL3 likely promote viral replication independently of their interaction with**
292 **phosphoinositides**

293 Recent data revealed that APOL1 and APOL3 play a role in lipid metabolism in podocytes and, more
294 specifically, in the regulation of the production of phosphatidylinositol-4-phosphate (PI(4)P), via an
295 indirect interaction with the PI4KB kinase [41]. PI(4)P is involved in Golgi secretory functions by
296 facilitating the recruitment of proteins that promote vesicular transport [42]. PI(4)P is also essential for
297 the establishment of efficient viral replication via the formation of membranes which serve as platforms
298 for the production of viral RNA [43,44]. APOL1 and/or APOL3 could thus impact ZIKV replication via
299 their ability to regulate the production of PI(4)P. To test this hypothesis, we first assessed APOL1 and
300 APOL3 localization in HMC3 cells. In the absence of specific antibodies for APOL1 and APOL3
301 validated for immunofluorescence assays, we investigated the localization of GFP-tagged versions of
302 APOL3 and APOL1 in HMC3 cells, together with markers for the Golgi apparatus (Fig. 4A), early or
303 late endosomes (Fig. S3). APOL1-GFP and GFP-APOL3 localized in closed proximity to the cis-Golgi
304 (Fig. 4A), where PI(4)P and PI4KB localize [45], and not in late nor early endosomes (Fig. S3). In line
305 with this, APOL1-GFP and GFP-APOL3 associated with PI4KB in HMC3 cells (Fig. 4B). Of note,
306 APOL1-GFP was also detected in vesicle-like structures whose identity could not be established (Fig.
307 4A, white arrow). They may represent lipid droplets or fragmented Golgi. The localization of APOL1-
308 GFP and GFP-APOL3 could not be investigated in ZIKV-infected cells since we observed that
309 transfection rendered cells non-permissive to viral infection.

310 We then performed experiments with a well-characterized PI4KB kinase inhibitor that decreases
311 PI(4)P expression [46]. We first analyzed by immunofluorescence the intensity of the PI(4)P signal in
312 cells treated for 24 h with different concentrations of the drug in HCM3 cells. The presence of the PI4KB
313 inhibitor triggered a dose-dependent decrease of the PI(4)P signal (Fig. 4C), suggesting that the drug is
314 efficient in HMC3 cells. We then infected cells with ZIKV in the presence of different concentration of
315 the inhibitor. Since the effect of APOL3 on ZIKV replication is dependent on IFNα2 (Fig. 3), the
316 analysis was also performed in stimulated cells. Coxsackie B3 virus (CVB3), an enterovirus that
317 replicates in a PI(4)P-dependent manner, was used as a positive control since its replication is sensitive
318 to the drug [47]. As negative controls, we used cells infected with WNV, whose replication is not
319 affected by the PI4KB inhibitor [48]. As previously shown in HeLa cells [47], a dose-dependent
320 reduction of the number of cells positive for the CVB3 viral protein 1 (VP1) was triggered by the
321 inhibitor treatment (Fig. 4D). As shown previously in monkey cells [48], WNV replication was
322 unaffected by the PI4KB inhibitor in HCM3 cells (Fig. 4D). ZIKV protein production was not sensitive
323 to the treatment with the PI4KB kinase inhibitor, independently of the presence of IFNα2 (Fig. 4D).
324 These experiments suggest that the pro-viral activities of APOL1 and APOL3 are not related to their
325 interaction with PI4KB or PI(4)P in microglial cells.

326

327 **MTA2 restricts ZIKV replication in IFNα2-stimulated human cells.**

328 MTA2 was identified in our screen as a gene with potent anti-ZIKV activities (Fig. 1). MTA2 shows
329 a very broad expression pattern and is strongly expressed in many tissues. It belongs to the NuRD
330 complex, which establishes transcriptional modulation of a number of target genes in vertebrates,
331 invertebrates and fungi [27]. Since its function has, so far, not been linked to viral infection, we decided
332 to investigate its potential antiviral activities further. To ensure that the MTA2-mediated inhibition of
333 viral replication was not restricted to HMC3 cells, experiments were also performed in Huh-7 hepatoma
334 cells, which are physiologically relevant for flavivirus infection and are thus extensively used in
335 *Flaviviridae* research. siRNAs targeting IFNAR1 were used as positive controls in these experiments.
336 siRNA-silencing reduced the levels of MTA2 and IFNAR1 mRNAs by at least 80%, when compared to
337 cells expressing scrambled control siRNAs, independently of the stimulation or infection status of
338 HMC3 and Huh-7 cells (Fig. 5A-D). MTA2 was included in our gene list because its expression
339 clustered with MX1 in T cells (Cerboni et al. in preparation). However, MTA2 mRNA abundance, as
340 measured by RT-qPCR analysis, remained unchanged upon IFNα2 treatment in both cells types (Fig.
341 5A and 5C), indicating that MTA2 is not an ISG in these cells.
342 Assessment of viral replication by RT-qPCR revealed that cell-associated viral RNA yields were
343 significantly higher in IFN-treated HMC3 cells silenced for MTA2 expression, as compared to controls
344 cells (Fig. 5E). This is in line with previous results (Fig. 1E). Cytometry analysis using anti-E antibodies
345 confirmed that MTA2 anti-ZIKV activities were dependent on the presence of IFN in HCM3 cells (Fig.
346 5F). Since MTA2 is not an ISG in HMC3 cells (Fig. 5A), these results suggest that MTA2 may require
347 an active IFN signaling to exert its anti-ZIKV activities in these cells. As in HMC3 cells, reduced
348 expression of MTA2 triggered a significant increase of intracellular viral RNA production in stimulated
349 Huh-7 cells (Fig. 5G). Reducing MTA2 expression had a more pronounced effect on the percentage of
350 infected cells that reducing IFNAR1 expression in stimulated Huh-7 cells (Fig. 5H). Albeit to a lesser
351 extent than in stimulated cells, MTA2 anti-ZIKV activity was also observed in non-stimulated Huh-7
352 cells by flow cytometry and RT-qPCR analysis (Fig. 5G and H).
353 The effect of MTA2 on viral protein production was further assessed by Western blot analysis using
354 anti-E and anti-NS5 antibodies in stimulated and unstimulated HMC3 and Huh-7 cells. These
355 experiments validated further the efficacy of the siRNAs against MTA2 in both cell lines (Fig. 5I and
356 5J). Expression of the viral proteins NS5 and E were increased in stimulated HMC3 and Huh-7 cells
357 expressing reduced levels of MTA2 or IFNAR1, as compared to control cells (Fig. 5I and 5J). In
358 agreement with the flow cytometry analysis (Fig. 5H), MTA2 anti-ZIKV activity was less dependent of
359 IFN-treatment in Huh-7 cells than in HMC3 cells (Fig. 5I and 5J). As observed in flow cytometry
360 analysis (Fig. 5H), MTA2 effect on viral protein production was more potent than the one of IFNAR1
361 in stimulated Huh-7 cells (Fig. 5J).
362 These results represent the first evidence of the ability of MTA2 to restrict the replication of any
363 virus.
364

365 **MTA2 restricts YFV and WNV replication in IFNα2-stimulated Huh-7 cells.**

366 We tested whether MTA2 was active against WNV and YFV in Huh-7 cells, which are permissive
367 to these 2 flaviviruses. As in previous experiments, higher MOIs were used in the presence of IFNα2.
368 Cytometry analysis revealed that MTA2 silencing significantly enhanced the replication of these 2
369 flaviviruses in an-IFN dependent manner (Fig. 6A and 6B), indicating that MTA2 antiviral activity is
370 broader that ZIKV. We then tested the effect of MTA2 silencing on the replication of VSV and MeV in
371 Huh-7 cells. Reduced expression of MTA2 decreased the number of cells infected with VSV and MeV
372 (Fig. 6C and 6D), independently of the IFN stimulation. This is consistent with the pro-HCV activity of
373 MTA2, as measured by titration in stimulated Huh-7.5 cells (Fig. 2B). MTA2 may thus possesses a
374 flavivirus genus-specific antiviral function.

375

376 **Discussion**

377 Several gain-of-fonction screens have been performed to identify ISGs that modulate flavivirus
378 infection. Pionner screens tested the activities of relatively small amounts of ISGs by overexpression
379 [49,50]. The first comprehensive overexpression screen in which more than 380 ISGs were evaluated
380 for antiviral activity against six viruses, including the *Flaviviridae* HCV, WNV and YFV, was published
381 in 2011 by Schoggins and collaborators [21]. To avoid potential physiological irrelevance induced by
382 gene overexpression, we opted for a silencing approach to identify genes that modulate ZIKV replication
383 in an IFN-induced state. We used a siRNA library which was designed in the context of an HIV project.
384 A limitation of our library is that targeted genes were selected based on a transcriptomic analysis of
385 primary T cells stimulated by contacts with activated monocytes (Cerboni et al. in preparation), and not
386 on ZIKV-target cells. Nevertheless, it contains a high fraction of core ISGs that overlaps with previous
387 screens [21,22]. Furthermore, most arrayed screens designed to identify cellular factors that modulate
388 ZIKV replication, including ours, monitored viral replication after a single round of infection, often by
389 assessing viral protein expression. Therefore, only genes that inhibit early stages of viral replication, up
390 to protein production, can be identified. Quantifying viral titers in supernatants collected from individual
391 wells of the first round of screening should identify genes that affect late stages of viral replication, such
392 as viral assembly, maturation and release, as well as viral infectivity. Alternatively, viral replication
393 could be monitored after several rounds of infection. Nevertheless, despite these two main limitations,
394 our screening strategy identified 21 genes affecting the number of cells positive for the viral protein E
395 in IFN-treated microglial cells.

396 Some hits were previously described as ISGs able to modulate ZIKV replication, such as IFITM3
397 [19,20] and LY6E [24], thus validating our screening approach. Despite being in our gene list, Viperin,
398 IFI6, PARP-12 and C19orf66, which are known to affect ZIKV replication in human cells [51–55], were
399 not identified as viral modulators by our strategy. They may have a weaker influence on viral replication
400 in HMC3 cells than in the cells in which their role was previously established [51–55]. In line with this

401 hypothesis, Viperin restricts the replication of several neurotropic flaviviruses in a cell type-dependent
402 manner [56]. One can also envisage that the expression levels of Viperin, IFI6, PARP-12 and C19orf66
403 are low in HMC3 cells, even when stimulated by IFNα2, and therefore are poorly, if at all downregulated
404 by specific siRNAs.

405 We validated the role of 5 hits as genes contributing to an optimal ZIKV replication in stimulated
406 HMC3 cells using RT-qPCR and flow cytometry analysis: LY6E, USP18, ISG15, APOL3 and NAPA.
407 The identification of LY6E as a gene enhancing ZIKV replication was expected, since it was previously
408 shown to promote the internalization of flaviviruses in U2OS human osteosarcoma cells [24]. Since
409 ISG15 and USP18 negatively regulate IFN signaling pathway [57,58], they are expected to act as broad
410 pro-viral ISGs. NAPA interacts with SNARE protein complexes to trigger their disassembly [59].
411 SNARE proteins belong to a superfamily of membrane fusion proteins that localize at the plasma
412 membrane, the Golgi apparatus and on different endocytic vesicles. They regulate the traffic of these
413 vesicles between the plasma membrane and the Golgi [60]. Several viruses, including influenza A virus
414 and VSV, hijack SNARE proteins to enter host cells [61]. SNARE complexes may thus contribute to
415 NAPA pro-viral activities. We validated the anti-viral functions of 4 screen hits in stimulated HMC3
416 cells infected with ZIKV: IRF9, IFITM3, MTA2 and GPD2. Identification of IRF9, which plays a key
417 role in ISG expression [25], and IFITM3, which restricts early stages of ZIKV infection [19,20],
418 validates our screening strategy. GPD2 is a mitochondrial protein involves in the metabolism of
419 glycerol. No link between GPD2 and viral infections has been established yet. However, it regulates
420 inflammatory response in macrophages [62]. Further experiments will be required to confirm that NAPA
421 and GPD2 have the ability to modulate ZIKV replication in stimulated human cells.

422 Experiments performed on cells infected with HCV or SARS-CoV-2 contributed to delineate the
423 spectrum of action of a selection of the screen hits. Our data illustrate once again that some ISGs have
424 virus-specific antiviral activities [63]. For instance, we found that ZIKV, but not the related HCV, was
425 sensitive to IFITM3 expression, confirming (HCV) and extending (ZIKV) recently reported data
426 [20,64]. Our data also confirm that some ISGs exert opposite effect on different viruses. For instance,
427 as described previously, LYE6 promotes the replication of ZIKV [24] but restricts that of SARS-CoV-
428 2 [35]. Viruses have developed numerous innovative strategies to evade ISG-mediated restriction
429 [65,66]. Hijacking individual ISG for promoting their replication is one of them. This hypothesis may
430 explain why, to our surprise, our screen recovered more pro-viral genes that antiviral ones.

431 Our results identified APOL3 and APOL1 as ISGs required for optimal ZIKV replication in HMC3
432 cells. The proviral activity of APOL1 was less dependent on IFN that the one of APOL3, which suggest
433 that both proteins act via different mechanisms. Reduced expression of APOL1 and APOL3 also
434 restricted the replication of WNV and DENV in stimulated HMC3 cells. In line with these findings,
435 over-expression of APOL1 was previously reported to increase YFV replication in Huh-7 cells [21].
436 VSV replication was highly reduced in the absence of one of these 2 genes. APOL1 has been reported
437 to act as an antiviral ISG in the context of infection with alphaviruses (Sindbis virus and Venezuelan

438 equine encephalitis virus) and human parainfluenza virus [21,67]. Its over-expression also inhibits HIV-
439 1 infection in monocytes [68]. Thus, APOL1 and APOL3 seem to behave like pro- or anti-viral ISG
440 depending on the virus, or have no obvious role (HCV). In line with our data on flaviviruses, a recent
441 report found that overexpression of APOL1 promoted infection with ZIKV and DENV-2, confirming a
442 proviral role for this factor [69]. However in this study, an increase of ZIKV, DENV-2 and HCV
443 replication was also reported in Huh-7.5 cells expressing siRNAs targeting APOL1 and APOL3 in the
444 absence of IFN treatment [69], yielding conflicting data that will deserve further investigation.
445 From our data, we formulated the hypothesis that APOL1 and APOL3 pro-viral activities could be
446 linked to their ability to bind to anionic phospholipids, including several phosphoinositides, in particular
447 PI(4)P [41]. Both APOL1 and APOL3 were detected in PI(4)P-containing liposomes [41]. Moreover,
448 reduced expression of APOL3 resulted in reduction of PI(4)P levels in podocytes [41]. PI(4)P plays a
449 pivotal role in the Golgi secretory functions by facilitating recruitment of proteins that promote vesicular
450 transport [42]. Our immunofluorescence data revealed that GFP-tagged version of APOL1 and APOL3
451 localize mainly in the Golgi, where PI(4)P localizes [42]. Numerous RNA viruses, including various
452 *Picornaviridae,* HCV, coronaviruses and parainfluenza type 3, rely on PI(4)P to build membranous
453 replication platform, where viral replication and assembly take place [70]. Flaviviruses are no exception
454 and also trigger intracellular membrane remodelling for the building of membranous replication
455 platforms [71]. Experiments conducted with a well-characterized PI4KB kinase inhibitor excluded the
456 possibility that APOL1 and APOL3 pro-viral effects depend on PI(4)P and its synthetizing protein,
457 PI4KB. In line with these results, PI(4)P are not important for the replication of WNV and the related
458 Usutu virus [48]. Other avenues should be thus explored to understand how APOL1 and APOL3
459 modulate the replication of several RNA viruses. Since APOL1 and APOL3 impact the replication of
460 unrelated viruses, they may be negative regulators of IFN signalling pathway, by, for instance,
461 contributing to the proper routing of members of the JAK/STAT pathway.
462 Our data revealed that MTA2 possesses potent antiviral function in the context of ZIKV, WNV and
463 YFV in stimulated cells, whereas its exhibited a proviral role for HCV, VSV and MeV. Reducing MTA2
464 expression in the presence of IFNα2 enhanced flaviviral replication to a level comparable to the
465 inhibition of IFNAR1. Despite being part of our gene list, MTA2 is not induced by IFN in HMC3 Huh-
466 7 cells but its antiviral activity was dependent on IFN in these cells. MTA2 may thus interact with an
467 ISG to act on viral replication. MTA2 is a component of the NuRD complex, an unusual complex which
468 exhibits ATP-dependent chromatin remodeling activity in addition to histone deacetylase activity [27].
469 The complex establishes transcriptional modulation of a number of target genes in vertebrates,
470 invertebrates and fungi [27]. MTA2 related activities have not, so far, been linked to innate immunity
471 in virus-infected cells. However, a link between the NuRD complex and STAT1-mediated IFN response
472 was established in the context of infection with the protozoan parasite *Toxoplasma gondii* [72]. A
473 *Toxoplasma* protein, named TgIST, translocates to the host cell nucleus where it recruits the complex
474 NuRD to STAT1-dependent promoters, resulting in altered chromatin and blocked STAT1-mediated

475 transcription [72]. Moreover, HDAC1, which is also a member of the NuRD complex, associates with
476 both STAT1 and STAT2 in human cells [73]. Furthermore, specific reduction of HDAC1 expression
477 inhibits IFNβ-induced transcription whereas HDAC1 overexpression enhances IFNβ-induced
478 transcription [73]. Finally, HDAC inhibitors block the formation of ISGF3 and this was associated with
479 impairment of STAT2 nuclear accumulation in mouse L929 cells [74]. These findings indicate a
480 fundamental role for deacetylase activity and HDAC1 in transcriptional control in response to IFN. One
481 could thus envisage that MTA2, within the NuRD complex, also interacts with STAT1 in cells
482 stimulated with IFN and favors its action locally. This interaction could restrict flavivirus infection,
483 possibly *via* enhancing the expression of a subset of flavivirus-specific ISGs.
484 Our work identified previously unrecognized genes that modulate the replication of RNA viruses in
485 an IFN-dependent way. Future studies combining transcriptomic analysis of IFN-treated cells and high
486 throughput loss-of-function screens will help define the interferome of cell types relevant for viral
487 infection. Such studies are primordial to continue investigating the complexity the IFN-mediated
488 antiviral program.
489
490
491 **Materials and Methods**
492
493 **Cells**
494 Human microglial cells (HMC3) were purchased from the American Type Culture Collection (ATCC,
495 CRL-3304). They were maintained in Dulbecco's modified Eagle's medium (DMEM) containing
496 GlutaMAX I and sodium pyruvate (Gibco), supplemented with 10% fetal bovine serum (FBS) and 1%
497 penicillin-streptomycin (P/S) (final concentration of 100 units/mL and 100 µg/mL, respectively)
498 (Sigma) and non-essential amino acids (GibcoTM NEAA 100X MEM, Life Technologies). Podocytes
499 were described previously [75]. They were grown at 33°C in Roswell Park Memorial Institute medium
500 (RPMI) containing GlutaMAX I (Gibco) and supplemented with 10% FBS and P/S. Before any
501 experiments, cells were differentiated during 7 days at 37°C. Human hepatocellular carcinoma Huh-7
502 cells [76], which were kindly given by Cinzia Traboni (IRBM, Pomezia, Italy), were maintained in
503 DMEM supplemented with 10% FBS and 1% P/S. Huh-7.5 cells (Apath, LLC), a subclone of Huh-7
504 cells [76] were cultured in DMEM supplemented with non-essential amino acids, 1mM sodium
505 pyruvate, 10% FBS and P/S. Vero NK cells, which are African green monkey kidney epithelial cells,
506 were purchased from ATCC and used for viral titration assays. They were maintained in DMEM
507 containing GlutaMAX I and sodium pyruvate (Gibco), supplemented with 10% FBS and P/S. *Aedes*
508 *albopictus* C6-36 cells were maintained in Leibovitz's L-15 medium containing 10% FBS, 1% P/S, 1%
509 Non-Essential Amino Acids Solution (Gibco) and 2% Tryptose Phosphate Browth (Gibco). Human lung
510 epithelial A549 cells were modified to stably express hACE2 using the pLenti6-hACE2 lentiviral

511 transduction, as described previously [77]. Cell cultures were verified to be mycoplasma free with the
512 MycoAlertTM Mycoplasma Detection Kit (Lonza).
513
514 **Virus stocks, titration and infection**
515 The Zika strain PF13 (kindly provided by V. M. Cao-Lormeau and D. Musso, Institut Louis Malardé,
516 Tahiti Island, French Polynesia) was isolated from a viremic patient in French Polynesia in 2013. Stocks
517 were produced on C6-36 cells. The Dengue 2 virus (DENV-2) strain Malaysia SB8553 was obtained
518 from the Centro de Ingeniería Genética y Biotecnología (CIGB), Cuba. The YFV Asibi strain and the
519 WNV Israeli strain IS-98-STI were provided by the Biological resource Center of the Institut Pasteur.
520 Stocks of DENV-2, YFV and WNV were produced on Vero NK cells. Viruses were concentrated by
521 polyethylene glycol 6000 precipitation and purified by centrifugation in a discontinued gradient of
522 sucrose. Flaviviruses were titrated on Vero NK cells by plaque assay as previously described [78] and
523 titers were expressed in plaque-forming units (PFU)/ml. The Measles Schwarz strain expressing GFP
524 (MeV-GFP) was described previously [40]. VSV Indiana and the CVB3 Nancy strain were kindly
525 provided by N. Escriou (Institut Pasteur) and M. Bessaud, respectively (Institut Pasteur). Modified
526 Vaccinia Ankara virus (MVA) expressing eGFP (MVA-GFP) was kindly provided by the ANRS via O.
527 Schwartz (Institut Pasteur). It was manufactured by Transgene (Illkirch-Graffenstaden, France).
528 The fluorescent marker, eGFP, is expressed under the control of the early promotor p11K7.5 and viral
529 preparations were purified by tangential flow filtration. HMC3 cells were infected at the following
530 MOIs: a MOI of 10 with DENV-2, 0,5 with WNV, 0,005 with VSV, 1 with MeV-GFP and 0,05 with
531 MVA-GFP. IFN-treated HMC3 cells were infected at a MOI of 20 with DENV-2, 5 with WNV, 0,01
532 with VSV, 2 with MeV-GFP and 0,25 with MVA-GFP. Huh-7 were infected at a MOI of 1 with YFV
533 and 0,25 with WNV. IFN-treated Huh-7 cells were infected at a MOI of 10 with YFV and WNV. Highly
534 cell culture-adapted HCV Jad strain was obtained following transfection of Huh-7.5 cells with *in vitro*
535 transcribed genome-length RNA as described previously [79–81]. Large volumes of HCV stocks were
536 prepared following infection at a MOI of 0.01 50% tissue culture infectious doses 50 (TCID50) per cell
537 with supernatants collected post-RNA transfection [82]. HCV infectious titers were determined by
538 TCID50 assays in Huh-7.5 cells as described previously [79]. IFN-treated Huh-7.5 cells were infected
539 at MOI of 3 TCID50/cell with HCV. The SARS-CoV-2 strain BetaCoV/France/IDF0372/2020
540 (historical) was supplied by the French National Reference Centre for Respiratory Viruses hosted by
541 Institut Pasteur (Paris, France) and headed by Pr. S. van der Werf. The human samples from which the
542 strain was isolated were provided by Dr. X. Lescure and Pr. Y. Yazdanpanah from the Bichat Hospital,
543 Paris, France and Dr. Vincent Foissaud, HIA Percy, Clamart, France, respectively. A549-ACE2 cells
544 were infected with SARS-CoV-2 at a MOI of 2.
545
546 **High throughput Screen**

547 Five hundreds HMC3 cells were seeded in 384-well microplates in the morning of day 1 using a
548 MultiDrop combi liquid dispenser (Thermo Fisher Scientific), in 40 µL of cell culture media. Cells were
549 allowed to adhere for 4 hours (+/-1h) before transfection with individual siRNAs (10nM) diluted in a
550 mix of OptiMEM (Life Technologies) and 0.05µL of Interferin reagent (Polyplus Transfection). siRNAs
551 were transfected using an Evo 150 with MCA384 (Tecan). The library contained 1158 siRNA targeting
552 386 genes. siRNA targeting KIF11 was used to assess the transfection efficiency. On day 2, cells were
553 treated with 1000U/ml of IFNα2a. Interferon was diluted into cell culture media and 10µL of the mix
554 was robotically transferred to each well (except non-treated controls). 24 hours after IFN treatment, cell
555 media was removed from siRNA-transfected plates and 40µL of the ZIKV PF13 strain, diluted to a final
556 concentration of 7,500 particles/well, was added to the plates with the MCA384 head (Tecan). ZIKV
557 titer was $6.5.10^8$ PFU/ml. Cells were then incubated 24 hours prior to fixation. Cells were fixed with 4%
558 of formaldehyde (Sigma-Aldrich) for 20 min, plates were then washed once with PBS and quenched
559 with NH4Cl (50mM) solution. Cells were then blocked with 1% BSA solution and permeabilized with
560 0.5% Triton X-100. Cells were next incubated for 60 min with mouse primary antibody anti-4G2 (1:500)
561 which reacts with flavivirus E proteins. Cells were then washed twice in PBS solution and incubated
562 with Alexa Fluor 488-coupled secondary antibodies (ThermoFisher Scientific). Nuclei were stained with
563 0.2 µg/ml Hoechst (Sigma). Images were acquired with an INCell2200 automated wide-field system
564 (GE Healthcare,) using a Nikon 10X/0.45, Plan Apo, CFI/60. Three fields per well were analyzed using
565 the INCell Analyzer 3.7 Workstation software. Two independent screens were performed. The mean
566 cell count and the percentages of infected cells were extracted from quantification.
567
568 **Data analysis and hit calling**
569 In the first analysis, data were processed using a software developed internally at the Biophenics
570 platform. For hit identification, the robust Z-score method was used under the assumption that most
571 siRNAs are inactive against ZIKV and can serve as controls [83,84]. Raw values were log-transformed
572 for cell count only to make the data more symmetric and close to normal distribution. In order to correct
573 for plate positional effects, median polishing [84] was applied to each analyzed feature. It iteratively
574 subtracts row, column and well median, computed from all plates within one screen. Hits for each
575 compound were identified as follows: sample median and median absolute deviation (MAD) were
576 calculated from the population of screening data points (named as sample) and used to compute Robust
577 Z-scores (RZ-scores) according to a formula, in which the reference population corresponds to the
578 siRNA-treated wells, and MAD is defined as the median of the absolute deviation from the median of
579 the corresponding wells:
580

$$rZ\text{-}Score = \frac{x - med(pop\ réf)}{1.4826\ x\ med(|pop\ réf - med(pop\ réf)|)}$$

581

582 A gene was identified as a 'hit', if the RZ-score was < -2 or > 2 pointing in the same direction for 2
583 siRNAs targeting the same gene in both screens. Final values in the hit table correspond to the RZ-score
584 of the second strongest siRNA. In the second analysis, data were process using an homemade script and
585 CellProfiler [85]. Nucleus and viral assembly sites detected by the E signal were counted. As in the first
586 analysis, rZ-Score and percentages of infected cells were quantified. Considering that each gene was
587 targeted by three individual siRNA, genes were clusterized as hits, if at least two over three of their
588 robust Z score absolute value were superior to 2. Genes were defined as hits when they were identified
589 in at least one of the analysis.
590
591 **Antibodies, plasmids and reagents**
592 The following primary antibodies were used in the study: anti-E MAb 4G2 hybridoma cells, anti-NS5-
593 ZIKV [86], anti-VSV-G (IE9F9, Kerafast), anti-CVB3 VP1 (M7064, Agilent), anti-SARS-CoV-2 S
594 protein mAb10 (1 µg/ml, a kind gift from H. Mouquet, Institut Pasteur, Paris, France), APOL1
595 (HPA018885, Sigma), MTA2 (8106, abcam), GM130 (12480, cell signaling), PI(4)P (Z-P004), PI(4)KB
596 (06-578, Milipore) and anti-actin (A5316, Sigma). Secondary antibodies were as followed: anti-mouse
597 Alexa 488 (A11001, Life Technologies), anti-mouse Alexa 680 (A21058, Life Technologies) and anti-
598 rabbit DyLight 800 (SA5-35571, TermoScientific). The PI4KB inhibitor (1881233-39-1,
599 MedChemExpress) and IFNα2a (Sigma-Aldrich, SRE0013) were used at the indicated concentration.
600 GFP-APOL3 et APOL3-GFP were subcloned into pcDNA.3.1 from templates previously described
601 [41].
602
603 **siRNA transfection**
604 HMC3 cells were transfected using INTERFERin transfection reagent (Polyplus Transfection). Huh-7
605 cells, Huh-7.5 cells and podocytes were transfected with siRNAs at 10 nM final concentration using
606 Lipofectamine RNAiMax (Life Technologies). All siRNAs were obtained from Dharmacon
607 (siGENOME-SMARTpool).
608
609 **RNA extraction and RT-qPCR assays**
610 Total RNAs were extracted from cell lysates using the NucleoSpin RNA II Kit (Macherey-Nagel)
611 following the manufacturer's protocol and were eluted in nuclease-free water. First-strand
612 complementary DNA synthesis was performed with the RevertAid H Minus M-MuLV Reverse
613 Transcriptase (Thermo Fisher Scientific). Quantitative real-time PCR was performed on a real-time PCR
614 system (QuantStudio 6 Flex, Applied Biosystems) with SYBR Green PCR Master Mix (Life
615 Technologies). Data were analyzed with the ΔΔCT method, with all samples normalized to GAPDH.
616 All experiments were performed in technical triplicate. Viral genome equivalents concentrations
617 (GE/ml) were determined by extrapolation from a standard curve generated from serial dilutions of the
618 plasmid encoding the full-length genome of the Zika strain MR766 [87] or plasmids encoding a

619 fragment of the RNA-dependent RNA polymerase (RdRp)-IP4 of SARS-CoV-2. HCV RNA was
620 quantified by one-step reverse transcription-quantitative PCR using 50 ng of total intracellular RNA and
621 TaqMan® Fast Virus 1-Step Master Mix (Applied Biosystems) with primers and probe targeting the
622 HCV 5′ nontranslated region as described previously [82]. Viral RNA levels were normalized with
623 respect to 18S RNA levels quantified in parallel using TaqMan ribosomal RNA control reagents
624 (Applied Biosystems). The products were analysed on a 7500 Fast Real-Time PCR system (Applied
625 Biosystems). Serial dilutions of a genome-length *in vitro* transcribed HCV RNA served to establish
626 standard curves and calculate HCV GE/µg total RNA concentrations. Primers and probe used for RT-
627 qPCR analysis are given in Table S2.
628
629 **Western blot analysis**
630 Cells were collected in RIPA buffer (Sigma) containing protease inhibitors (Roche Applied Science).
631 Cell lysates were normalized for protein content with Pierce 660nm Protein Assay (Thermo Scientific),
632 boiled in NuPAGE LDS sample buffer (Thermo Fisher Scientific) in non-reducing conditions. Samples
633 were separated by SDS-PAGE (NuPAGE 4–12% Bis-Tris Gel, Life Technologies) with MOPS running
634 buffer. Separated proteins were transferred to a nitrocellulose membrane (Bio-Rad). After blocking with
635 PBS-Tween-20 0.1% (PBST) containing 5% milk for 1 h at RT, the membrane was incubated overnight
636 at 4°C with primary antibodies diluted in blocking buffer. Finally, the membranes were incubated for 1
637 h at RT with secondary antibodies diluted in blocking buffer, washed, and scanned using an Odyssey
638 CLx infrared imaging system (LI-COR Bioscience).
639
640 **Flow cytometry**
641 Infected cells were fixed with cytofix/cytoperm kit (BD Pharmingen) and stained using the indicated
642 primary and secondary antibodies. Non-infected, antibody-stained samples served as controls for signal
643 background. Data were acquired using Attune NxT Acoustic Focusing Cytometer (Life Technologies)
644 and analyzed using FlowJo software.
645
646 **Immunofluorescence assay**
647 Cells were fixed with PFA 4% (Sigma) during 20min. Cells were permeabilized with PBS Triton X-100
648 (0.5%) for 15min at RT. After washing with PBS, they were incubated for 30 min with PBS + 0.05%
649 Tween 20 + 5% BSA. The slides were then incubated overnight at 4°C with primary antibodies diluted
650 in PBS. After washing with PBS, they were incubated for 1 h with secondary antibodies and washed
651 with PBS. Nuclei were stained using PBS/NucBlue (Life Technologies, R37606). The mounting
652 medium used is the Prolong gold (Life Technologies, P36930). All preparations were observed with a
653 confocal microscope (ZEISS LSM 700 inverted) and images were acquired with the ZEN software.
654
655 **Statistical analysis.**

656 Data are presented as means ± SD and were analyzed using GraphPad Prism 7. Statistical analysis of
657 percentage values or fold enrichment values were performed on logit or log-transformed values,
658 respectively. Statistical analysis was performed with two tailed paired t-test or by one- or two-way
659 analysis of variance (ANOVA) with Dunnet's multiple comparisons test. Each experiment was
660 performed at least twice, unless otherwise stated. Statistically significant differences are indicated as
661 follows: *: $p < 0.05$, **: $p < 0.01$ and ***: $p < 0.001$; ns, not significant.
662
663
664 **Acknowledgments**
665 We thank Dr. M.A. Saleem (University of Bristol, UK) for generously providing the podocytes (via E.
666 Pays, Université Libre de Bruxelles, Belgium); C.M. Rice (Rockefeller University, New York, USA)
667 for Huh-7.5 cells; Cinzia Traboni (IRBM, Pomezia, Italy) for Huh-7 cells; M. Bessaud (Institut Pasteur)
668 for the CVB3 Nancy strain; N. Escriou (Institut Pasteur) for the VSV Indiana strain and anti-VSV-G
669 antibodies; V. M. Cao-Lormeau and D. Musso (Institut Louis Malardé, Tahiti Island, French Polynesia)
670 for the ZIKV-PF13 strain; L. Hermida and G. Enrique Guillen Nieto from the Centro de Ingeniería
671 Genética y Biotecnología (CIGB), Cuba, for the DENV-2 strain Malaysia SB8553; T. Wakita (NIID,
672 Tokyo, Japan) for pJFH1 HCV cDNA; R. Bartenschlager (University of Heidelberg, Germany) for
673 pJFH1-2EI3-adapt cDNA; the French National Reference Centre for Respiratory Viruses hosted by
674 Institut Pasteur (France) and headed by S. van der Werf for providing the historical SARS-CoV-2 viral
675 strains; A. Merits (University of Tartu, Estonia) for anti-ZIKV NS5 antibodies; P. Desprès (Université
676 de la Réunion, PIMIT) for 4G2 hybridoma cells; H. Mouquet (Institut Pasteur) for anti-SARS-CoV-2 S
677 antibodies; M. Evans (Icahn School of Medicine at Mount Sinai, New York, USA) for the plasmid
678 encoding the full-length Zika MR766 genome; F. Porrot and O. Schwartz (Institut Pasteur) for
679 producing and sharing the MVA-GFP, C. Combredet (Institut Pasteur) for producing MeV-GFP; as well
680 as E. Pays and S. Uzureau (Université Libre de Bruxelles, Belgium) for APOL1 and APOL3 plasmids
681 and for stimulating APOL-focused discussions. We are grateful to the members of our laboratories for
682 helpful discussions and technical advice. Finally, we thank Emeline Perthame (Bioinformatics and
683 Biostatistics HUB, Institut Pasteur) for her help in statistical analysis.
684
685 **Declaration of interests.** The authors declare no competing interests.
686
687 **References**
688
689 1. Woolhouse M, Scott F, Hudson Z, Howey R, Chase-Topping M. Human viruses:
690 discovery and emergence. Philos Trans R Soc Lond B Biol Sci. 2012;367: 2864–71.
691 doi:10.1098/rstb.2011.0354
692 2. Streicher F, Jouvenet N. Stimulation of Innate Immunity by Host and Viral RNAs.

693 Trends in Immunology. 2019;40: 1134–1148. doi:10.1016/j.it.2019.10.009
694 3. Schoggins JW. Recent advances in antiviral interferon-stimulated gene biology.
695 F1000Res. 2018;7. doi:10.12688/f1000research.12450.1
696 4. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferome
697 v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res.
698 2013;41: D1040-6. doi:10.1093/nar/gks1215
699 5. Touzot M, Grandclaudon M, Cappuccio A, Satoh T, Martinez-Cingolani C, Servant N,
700 et al. Combinatorial flexibility of cytokine function during human T helper cell
701 differentiation. Nat Commun. 2014;5: 3987. doi:10.1038/ncomms4987
702 6. Mostafavi S, Yoshida H, Moodley D, LeBoité H, Rothamel K, Raj T, et al. Parsing the
703 interferon transcriptional network and its disease associations. Cell. 2016;164: 564–578.
704 doi:10.1016/j.cell.2015.12.032
705 7. Schneider WM, Chevillotte MD, Rice CM. Interferon-Stimulated Genes: A Complex
706 Web of Host Defenses. Annu Rev Immunol. 2014;32: 513–545. doi:10.1146/annurev-
707 immunol-032713-120231
708 8. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nat
709 Microbiol. 2020. doi:10.1038/s41564-020-0714-0
710 9. Ashraf U, Ye J, Ruan X, Wan S, Zhu B, Cao S. Usutu virus: an emerging flavivirus in
711 Europe. Viruses. 2015;7: 219–38. doi:10.3390/v7010219
712 10. Pierson TC, Diamond MS. The emergence of Zika virus and its new clinical
713 syndromes. Nature. 2018;560: 573–581. doi:10.1038/s41586-018-0446-y
714 11. Matusali G, Houzet L, Satie A-P, Mahé D, Aubry F, Couderc T, et al. Zika virus
715 infects human testicular tissue and germ cells. J Clin Invest. 2018;128: 4697–4710.
716 doi:10.1172/JCI121735
717 12. Rossi SL, Tesh RB, Azar SR, Muruato AE, Hanley KA, Auguste AJ, et al.
718 Characterization of a Novel Murine Model to Study Zika Virus. Am J Trop Med Hyg.
719 2016;94: 1362–9. doi:10.4269/ajtmh.16-0111
720 13. Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, et al. A Mouse
721 Model of Zika Virus Pathogenesis. Cell Host Microbe. 2016;19: 720–30.
722 doi:10.1016/j.chom.2016.03.010
723 14. Tripathi S, Balasubramaniam VR, Brown JA, Mena I, Grant A, Bardina SV, et al. A
724 novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and
725 host inflammatory immune responses. PLoS Pathog. 2017;13: e1006258.
726 doi:10.1371/journal.ppat.1006258
727 15. Xia H, Luo H, Shan C, Muruato AE, Nunes BTD, Medeiros DBA, et al. An
728 evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nat
729 Commun. 2018;9: 414. doi:10.1038/s41467-017-02816-2
730 16. Meertens L, Labeau A, Dejarnac O, Cipriani S, Sinigaglia L, Bonnet-Madin L, et al.
731 Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune
732 Responses. Cell Rep. 2017;18: 324–333. doi:10.1016/j.celrep.2016.12.045
733 17. Xu P, Shan C, Dunn TJ, Xie X, Xia H, Gao J, et al. Role of microglia in the
734 dissemination of Zika virus from mother to fetal brain. PLoS Negl Trop Dis. 2020;14.
735 doi:10.1371/journal.pntd.0008413
736 18. Wang J, Liu J, Zhou R, Ding X, Zhang Q, Zhang C, et al. Zika virus infected primary
737 microglia impairs NPCs proliferation and differentiation. Biochem Biophys Res Commun.
738 2018;497: 619–625. doi:10.1016/j.bbrc.2018.02.118
739 19. Savidis G, Perreira JM, Portmann JM, Meraner P, Guo Z, Green S, et al. The IFITMs
740 Inhibit Zika Virus Replication. Cell Rep. 2016;15: 2323–30. doi:10.1016/j.celrep.2016.05.074
741 20. Monel B, Compton AA, Bruel T, Amraoui S, Burlaud-Gaillard J, Roy N, et al. Zika
742 virus induces massive cytoplasmic vacuolization and paraptosis-like death in infected cells.

743 EMBO J. 2017;36: 1653–1668. doi:10.15252/embj.201695597
744 21. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A
745 diverse range of gene products are effectors of the type I interferon antiviral response. Nature.
746 2011;472: 481–5. doi:10.1038/nature09907
747 22. Liu S-Y, Sanchez DJ, Aliyari R, Lu S, Cheng G. Systematic identification of type I
748 and type II interferon-induced antiviral factors. PNAS. 2012;109: 4239–4244.
749 23. Groth-Pedersen L, Aits S, Corcelle-Termeau E, Petersen NHT, Nylandsted J, Jäättelä
750 M. Identification of cytoskeleton-associated proteins essential for lysosomal stability and
751 survival of human cancer cells. PLoS One. 2012;7: e45381.
752 doi:10.1371/journal.pone.0045381
753 24. Hackett BA, Cherry S. Flavivirus internalization is regulated by a size-dependent
754 endocytic pathway. Proc Natl Acad Sci U S A. 2018;115: 4246–4251.
755 doi:10.1073/pnas.1720032115
756 25. Paul A, Tang TH, Ng SK. Interferon Regulatory Factor 9 Structure and Regulation.
757 Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01831
758 26. Smith S, Weston S, Kellam P, Marsh M. IFITM proteins-cellular inhibitors of viral
759 entry. Curr Opin Virol. 2014;4: 71–77. doi:10.1016/j.coviro.2013.11.004
760 27. Lai AY, Wade PA. NuRD: A multi-faceted chromatin remodeling complex in
761 regulating cancer biology. Nat Rev Cancer. 2011;11: 588–596. doi:10.1038/nrc3091
762 28. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and
763 genomic hepatitis C virus RNA replication. J Virol. 2002;76: 13001–14.
764 29. Sumpter R, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating
765 intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication
766 through a cellular RNA helicase, RIG-I. J Virol. 2005;79: 2689–99.
767 doi:10.1128/JVI.79.5.2689-2699.2005
768 30. Mukherjee A, Di Bisceglie AM, Ray RB. Hepatitis C virus-mediated enhancement of
769 microRNA miR-373 impairs the JAK/STAT signaling pathway. J Virol. 2015;89: 3356–65.
770 doi:10.1128/JVI.03085-14
771 31. Li Y, Ma MX, Qin B, Lin L-T, Richardson CD, Feld J, et al. The Ubiquitin-Specific
772 Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity. Mediators
773 of Inflammation. 2019;2019: e3124745. doi:10.1155/2019/3124745
774 32. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, et al. Silencing of
775 USP18 Potentiates the Antiviral Activity of Interferon Against Hepatitis C Virus Infection.
776 Gastroenterology. 2006;131: 1584–1591. doi:10.1053/j.gastro.2006.08.043
777 33. Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, et al.
778 Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog.
779 2011;7: e1002289. doi:10.1371/journal.ppat.1002289 PPATHOGENS-D-11-00682 [pii]
780 34. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a
781 ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro:
782 implications for chronic infection and response to treatment. J Gen Virol. 2010;91: 382–388.
783 doi:10.1099/vir.0.015388-0
784 35. Pfaender S, Mar KB, Michailidis E, Kratzel A, Boys IN, V'kovski P, et al. LY6E
785 impairs coronavirus fusion and confers immune control of viral disease. Nature Microbiology.
786 2020;5: 1330–1339. doi:10.1038/s41564-020-0769-y
787 36. Vanhollebeke B, Pays E. The function of apolipoproteins L. Cell Mol Life Sci.
788 2006;63: 1937–1944. doi:10.1007/s00018-006-6091-x
789 37. Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJG. The apolipoprotein L gene
790 cluster has emerged recently in evolution and is expressed in human vascular tissue.
791 Genomics. 2002;79: 539–546. doi:10.1006/geno.2002.6729
792 38. Malakhova OA, Kim KI, Luo J-K, Zou W, Kumar KGS, Fuchs SY, et al. UBP43 is a

793 novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO
794 J. 2006;25: 2358–2367. doi:10.1038/sj.emboj.7601149
795 39. Alcendor DJ. Zika Virus Infection of the Human Glomerular Cells: Implications for
796 Viral Reservoirs and Renal Pathogenesis. J Infect Dis. 2017;216: 162–171.
797 doi:10.1093/infdis/jix171
798 40. Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, et al. A
799 Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune
800 Responses in Macaques and Transgenic Mice. Journal of Virology. 2003;77: 11546–11554.
801 doi:10.1128/JVI.77.21.11546-11554.2003
802 41. Uzureau S, Lecordier L, Uzureau P, Hennig D, Graversen JH, Homblé F, et al.
803 APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3
804 Control of Actomyosin. Cell Rep. 2020;30: 3821-3836.e13. doi:10.1016/j.celrep.2020.02.064
805 42. Waugh MG. The Great Escape: how phosphatidylinositol 4-kinases and PI4P promote
806 vesicle exit from the Golgi (and drive cancer). Biochem J. 2019;476: 2321–2346.
807 doi:10.1042/BCJ20180622
808 43. Delang L, Paeshuyse J, Neyts J. The role of phosphatidylinositol 4-kinases and
809 phosphatidylinositol 4-phosphate during viral replication. Biochem Pharmacol. 2012;84:
810 1400–1408. doi:10.1016/j.bcp.2012.07.034
811 44. Strating JR, van Kuppeveld FJ. Viral rewiring of cellular lipid metabolism to create
812 membranous replication compartments. Curr Opin Cell Biol. 2017;47: 24–33.
813 doi:10.1016/j.ceb.2017.02.005
814 45. Daboussi L, Costaguta G, Ghukasyan R, Payne GS. Conserved role for Gga proteins
815 in phosphatidylinositol 4-kinase localization to the trans-Golgi network. PNAS. 2017;114:
816 3433–3438.
817 46. Rutaganira FU, Fowler ML, McPhail JA, Gelman MA, Nguyen K, Xiong A, et al.
818 Design and Structural Characterization of Potent and Selective Inhibitors of
819 Phosphatidylinositol 4 Kinase IIIβ. J Med Chem. 2016;59: 1830–1839.
820 doi:10.1021/acs.jmedchem.5b01311
821 47. Hsu N-Y, Ilnytska O, Belov G, Santiana M, Chen Y-H, Takvorian PM, et al. Viral
822 reorganization of the secretory pathway generates distinct organelles for RNA replication.
823 Cell. 2010;141: 799–811. doi:10.1016/j.cell.2010.03.050
824 48. Martín-Acebes MA, Blázquez A-B, Jiménez de Oya N, Escribano-Romero E, Saiz J-
825 C. West Nile virus replication requires fatty acid synthesis but is independent on
826 phosphatidylinositol-4-phosphate lipids. PLoS One. 2011;6: e24970.
827 doi:10.1371/journal.pone.0024970
828 49. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, et al. Identification of five
829 interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J
830 Virol. 2010;84: 8332–41. doi:10.1128/JVI.02199-09
831 50. Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, et al.
832 Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C
833 virus replication. J Viral Hepat. 2006;13: 690–700. doi:10.1111/j.1365-2893.2006.00732.x
834 51. Van der Hoek KH, Eyre NS, Shue B, Khantisitthiporn O, Glab-Ampi K, Carr JM, et
835 al. Viperin is an important host restriction factor in control of Zika virus infection. Sci Rep.
836 2017;7: 4475. doi:10.1038/s41598-017-04138-1
837 52. Richardson RB, Ohlson MB, Eitson JL, Kumar A, McDougal MB, Boys IN, et al. A
838 CRISPR screen identifies IFI6 as an ER-resident interferon effector that blocks flavivirus
839 replication. Nat Microbiol. 2018. doi:10.1038/s41564-018-0244-1
840 53. Li L, Zhao H, Liu P, Li C, Quanquin N, Ji X, et al. PARP12 suppresses Zika virus
841 infection through PARP-dependent degradation of NS1 and NS3 viral proteins. Sci Signal.
842 2018;11: eaas9332. doi:10.1126/scisignal.aas9332

843 54. Wu Y, Yang X, Yao Z, Dong X, Zhang D, Hu Y, et al. C19orf66 interrupts Zika virus
844 replication by inducing lysosomal degradation of viral NS3. PLOS Neglected Tropical
845 Diseases. 2020;14: e0008083. doi:10.1371/journal.pntd.0008083
846 55. Vanwalscappel B, Gadea G, Desprès P. A Viperin Mutant Bearing the K358R
847 Substitution Lost its Anti-ZIKA Virus Activity. Int J Mol Sci. 2019;20: E1574.
848 doi:10.3390/ijms20071574
849 56. Lindqvist R, Kurhade C, Gilthorpe JD, Överby AK. Cell-type- and region-specific
850 restriction of neurotropic flavivirus infection by viperin. Journal of Neuroinflammation.
851 2018;15: 80. doi:10.1186/s12974-018-1119-3
852 57. Perng Y-C, Lenschow DJ. ISG15 in antiviral immunity and beyond. Nat Rev
853 Microbiol. 2018;16: 423–439. doi:10.1038/s41579-018-0020-5
854 58. Honke N, Shaabani N, Zhang D-E, Hardt C, Lang KS. Multiple functions of USP18.
855 Cell Death Dis. 2016;7: e2444–e2444. doi:10.1038/cddis.2016.326
856 59. Huang X, Sun S, Wang X, Fan F, Zhou Q, Lu S, et al. Mechanistic insights into the
857 SNARE complex disassembly. Science Advances. 2019;5: eaau8164.
858 doi:10.1126/sciadv.aau8164
859 60. Jahn R, Scheller RH. SNAREs — engines for membrane fusion. Nat Rev Mol Cell
860 Biol. 2006;7: 631–643. doi:10.1038/nrm2002
861 61. Pirooz SD, He S, Zhang T, Zhang X, Zhao Z, Oh S, et al. UVRAG is required for
862 virus entry through combinatorial interaction with the class C-Vps complex and SNAREs.
863 Proc Natl Acad Sci U S A. 2014;111: 2716–2721. doi:10.1073/pnas.1320629111
864 62. Langston PK, Nambu A, Jung J, Shibata M, Aksoylar HI, Lei J, et al. Glycerol
865 phosphate shuttle enzyme GPD2 regulates macrophage inflammatory responses. Nat
866 Immunol. 2019;20: 1186–1195. doi:10.1038/s41590-019-0453-7
867 63. Schoggins JW. Interferon-Stimulated Genes: What Do They All Do? Annual Review
868 of Virology. 2019;6: 567–584. doi:10.1146/annurev-virology-092818-015756
869 64. Tartour K, Nguyen XN, Appourchaux R, Assil S, Barateau V, Bloyet LM, et al.
870 Interference with the production of infectious viral particles and bimodal inhibition of
871 replication are broadly conserved antiviral properties of IFITMs. PLoS Pathog. 2017;13:
872 e1006610. doi:10.1371/journal.ppat.1006610
873 65. García-Sastre A. Ten Strategies of Interferon Evasion by Viruses. Cell Host Microbe.
874 2017;22: 176–184. doi:10.1016/j.chom.2017.07.012
875 66. Schulz KS, Mossman KL. Viral Evasion Strategies in Type I IFN Signaling – A
876 Summary of Recent Developments. Front Immunol. 2016;7. doi:10.3389/fimmu.2016.00498
877 67. Schoggins JW, Macduff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, et al.
878 Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity.
879 Nature. 2013. doi:10.1038/nature12862
880 68. Taylor HE, Khatua AK, Popik W. The innate immune factor apolipoprotein L1
881 restricts HIV-1 infection. J Virol. 2014;88: 592–603. doi:10.1128/JVI.02828-13
882 69. Yamane D, Feng H, Rivera-Serrano EE, Selitsky SR, Hirai-Yuki A, Das A, et al.
883 Basal expression of interferon regulatory factor 1 drives intrinsic hepatocyte resistance to
884 multiple RNA viruses. Nat Microbiol. 2019;4: 1096–1104. doi:10.1038/s41564-019-0425-6
885 70. Burke JE, McPhail JA, Rathinaswamy M, Jenkins ML. Defining how viruses
886 manipulate lipid phosphoinositides through activation of PI4P kinases to mediate viral
887 replication. The FASEB Journal. 2020;34: 1–1. doi:10.1096/fasebj.2020.34.s1.02060
888 71. Gillespie LK, Hoenen A, Morgan G, Mackenzie JM. The Endoplasmic Reticulum
889 Provides the Membrane Platform for Biogenesis of the Flavivirus Replication Complex.
890 Journal of Virology. 2010;84: 10438–10447. doi:10.1128/JVI.00986-10
891 72. Olias P, Etheridge RD, Zhang Y, Holtzman MJ, Sibley LD. Toxoplasma Effector
892 Recruits the Mi-2/NuRD Complex to Repress STAT1 Transcription and Block IFN-γ-

Dependent Gene Expression. Cell Host Microbe. 2016;20: 72–82. doi:10.1016/j.chom.2016.06.006

73. Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. PNAS. 2003;100: 14742–14747. doi:10.1073/pnas.2433987100

74. Vlasáková J, Nováková Z, Rossmeislová L, Kahle M, Hozák P, Hodný Z. Histone deacetylase inhibitors suppress IFNα-induced up-regulation of promyelocytic leukemia protein. Blood. 2007;109: 1373–1380. doi:10.1182/blood-2006-02-003418

75. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002;13: 630–638. doi:10.1681/ASN.V133630

76. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42: 3858–3863.

77. Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah MM, et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 2021;40: e107405. doi:10.15252/embj.2020107405

78. Chazal M, Beauclair G, Gracias S, Najburg V, Simon-Loriere E, Tangy F, et al. RIG-I Recognizes the 5' Region of Dengue and Zika Virus Genomes. Cell Rep. 2018;24: 320–328. doi:10.1016/j.celrep.2018.06.047

79. Boukadida C, Marnata C, Montserret R, Cohen L, Blumen B, Gouttenoire J, et al. NS2 proteins of GB virus B and hepatitis C virus share common protease activities and membrane topologies. J Virol. 2014;88: 7426–44. doi:10.1128/JVI.00656-14

80. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11: 791–6. doi:10.1038/nm1268

81. Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol. 2007;81: 13168–79. doi:10.1128/JVI.01362-07

82. Aicher S, Kakkanas A, Cohen L, Blumen B, Oprisan G, Njouom R, et al. Differential regulation of the Wnt/beta-catenin pathway by hepatitis C virus recombinants expressing core from various genotypes. Sci Rep. 2018;8: 11185. doi:10.1038/s41598-018-29078-2

83. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol. 2006;24: 167–175. doi:10.1038/nbt1186

84. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, et al. Statistical Methods for Analysis of High-Throughput RNA Interference Screens. Nat Methods. 2009;6: 569–575. doi:10.1038/nmeth.1351

85. McQuin C, Goodman A, Chernyshev V, Kamentsky L, Cimini BA, Karhohs KW, et al. CellProfiler 3.0: Next-generation image processing for biology. PLOS Biology. 2018;16: e2005970. doi:10.1371/journal.pbio.2005970

86. Mutso M, Saul S, Rausalu K, Susova O, Žusinaite E, Mahalingam S, et al. Reverse genetic system, genetically stable reporter viruses and packaged subgenomic replicon based on a Brazilian Zika virus isolate. J Gen Virol. 2017;98: 2712–2724. doi:10.1099/jgv.0.000938

87. Schwarz MC, Sourisseau M, Espino MM, Gray ES, Chambers MT, Tortorella D, et al. Rescue of the 1947 Zika Virus Prototype Strain with a Cytomegalovirus Promoter-Driven cDNA Clone. mSphere. 2016;1. doi:10.1128/mSphere.00246-16

942 **Figure legends**

943

944 **Figure 1**. **A loss of function screen identified genes modulating ZIKV replication in IFN-**
945 **stimulated human microglial cells**. (A) Scheme summarizing the screen conditions. (B, C) Scatter
946 plots showing the rZ-score obtained in the 1st (B) and second analysis (C) of the 2 screens. The green
947 line represents the linear regression, as compared to the expected perfect correlation (dotted black line).
948 Antiviral and proviral hits are depicted in red and blue, respectively. (D) List of the antiviral and proviral
949 hits as identified by the 2 analysis of the 2 screens. Assessment of the antiviral (E, F) and proviral (G,
950 H) activities of some hits. HMC3 cells were transfected with either pool of 3 siRNAs against the
951 indicated candidate gene or non-targeting (NT) siRNAs, treated with IFNα2 (200U/mL) for 24 hours
952 and infected with ZIKV (at an MOI of 5 PFU/cell) for 24 hours. Control cells transfected with NT
953 siRNA in the absence of IFNα2 treatment (NT-IFN) are included. (E, G) Cell-associated viral RNA was
954 quantified by RT-qPCR and expressed as genome equivalents (GE) per µg of total cellular RNA. (F, H)
955 The number of cells positive for viral protein E was assessed by flow cytometry and are expressed
956 relatively to the NT+IFN control of each experiment. Data are means ± SD of three or four independent
957 experiments, *p<0.05, **p<0.01,***p<0.001, paired t-tests.

958

959 **Figure 2. Effect of a selection of candidate genes on HCV and SARS-CoV-2 replication. (**A-D).
960 Huh-7.5 cells were transfected with a pool of 3 siRNAs against selected candidates (antiviral and
961 proviral genes, as identified in the ZIKV screen (Fig. 1), are in red and blue, respectively) or non-
962 targeting (NT) siRNAs, treated with IFNα2 (200U/mL) for 24 hours, then infected with HCV at a MOI
963 of 3 TCID50/cell for 48 hours. (A, C) Cell-associated viral RNA was quantified by RT-qPCR and
964 expressed as genome equivalents (GE) per µg of total cellular RNA. (B, D) Release of infectious HCV
965 particles was determined by TCID50 assays. Data are expressed relatively to the NT+IFN control of
966 each experiment. Plotted values are expressed relative to mean NT+IF across experiements and
967 represent means ± SD of two independent experiments each in duplicates, *p<0.05,
968 **p<0.01,***p<0.001, ****p<0.0001 paired t-tests. (E-H). A549-ACE2 cells were transfected with a
969 pool of 3 siRNAs against selected candidates (antiviral genes in red, proviral genes in blue) or non-
970 targeting (NT) siRNAs, treated with IFNα2 (200U/mL) for 24 hours and infected with SARS-CoV-2 at
971 a MOI of 2 for 24 hours. (E, G) Cell-associated viral RNA was quantified by RT-qPCR and expressed
972 as genome equivalents (GE) per µg of total cellular RNA. (F, H) The number of cells positive for the
973 viral protein spike (S) was assessed by flow cytometry Data are expressed relatively to the NT+IFN
974 control of each experiment. Data are means ± SD of triplicates of one experiment, *p<0.05,
975 **p<0.01,***p<0.001, paired t-tests.

976

977 **Figure 3. Effect of reduced expression of APOL1 and APOL3 on the replication of a panel of**
978 **viruses in HMC3 cells and podocytes.** (A, E) *APOL1* mRNA and *APOL3* mRNA abundance were
979 quantified by RT-qPCR analysis in HMC3 cells or podocytes treated or not with IFNα2 (200U/mL) for
980 24 hours and expressed as copy numbers per μg of total cellular RNA. HMC3 cells (B) or podocytes (F)
981 were transfected with pool of 3 siRNAs targeting *APOL1, APOL3* and *USP18* mRNAs or with non-
982 targeting (NT) control siRNAs. The relative amounts of *APOL1, APOL3* and *USP18* mRNAs were
983 determined by RT-qPCR analysis and were normalized to that of GAPDH mRNA. They are expressed
984 as compared to abundance relative to cells transfected with control NT siRNAs. HMC3 cells (C) or
985 podocytes (G) were transfected with the indicated siRNAs, treated, or not, with IFNa2 (200U/mL) for
986 24 hours, and infected with ZIKV for 24 hours. HMC3 cells were infected at a MOI of 2 and podocytes
987 at a MOI of 1. The percentages of cells that were positive for the viral E proteins were determined by
988 flow cytometric analysis. Data are expressed relatively to the siRNA NT control of each experiment.
989 HMC3 cells (D) or podocytes (H) were treated with IFNα2 (200U/mL), transfected with the indicated
990 siRNAs pools and subjected to Western blotting analysis with antibodies against the indicated proteins.
991 (I) HMC3 cells were transfected with the indicated siRNAs pools, treated with IFNa2 (200U/mL) for
992 24 hours and infected with the indicated viruses for 18 to 24 hours, at the MOI indicated in the MM
993 section. The percentages of the cells positive for viral proteins or GFP were determined by flow
994 cytometric analysis. Data are means ± SD of three or four independent experiments, *p<0.05,
995 **p<0.01,***p<0.001, paired t-tests.
996
997 **Figure 4. APOL1 and APOL3 promote viral replication independently of their interaction with**
998 **phosphoinositides**. HMC3 cells were transfected with GFP-tagged versions of APOL1 and APOL3.
999 Thirty hours later, they were stained with antibodies recognizing GM130 (A) or PI4KB (B) and with
1000 NucBlue to detect nuclei. Images are representative of numerous observations over 2 independent
1001 experiments. The white arrow shows an APOL1-GFP-positive vesicle. (C) HCM3 cells were treated
1002 with different concentrations of the PI4KB inhibitor and were stained for PI(4)P. (D) HMC3 cells treated
1003 with different doses of PI4KB inhibitor were infected with CVB3, WNV or ZIKV, in the presence or
1004 absence of IFNα2 (200U/mL). The percentages of the cells positive for viral proteins were determined
1005 by flow cytometric analysis. Data are means ± SD of three independent experiments, *p<0.05,
1006 **p<0.01,***p<0.001, one-way ANOVA.
1007

1008 **Figure 5. MTA2 restricts ZIKV replication in IFNα2-stimulated cells.** HMC3 (A, B, E, F, I) and
1009 Huh-7 cells (C, D, G, H, J) were transfected with pool of 3 siRNAs targeting *MTA2* or *IFNAR1* mRNAs
1010 or non-targeting (NT) control siRNAs, treated or not with IFNα2 (100U/mL) for 24 hours, and infected
1011 with ZIKV (MOI of 1 for HMC3 cells, MOI of 5 for Huh-7 cells) for 24 hours. (A-D) The relative
1012 amounts of *MTA2* and *IFNAR1* mRNAs were determined by RT-qPCR analysis and normalized to that

1013 of *GAPDH* mRNA and siRNA-NT without IFN. (E, G) Cell-associated viral RNA was quantified by
1014 RT-qPCR and expressed as genome equivalents (GE) per µg of total cellular RNA. (F, H) Number of
1015 infected cells was assessed by staining of viral protein E and flow cytometry analysis. (I, J) Cells were
1016 treated with IFNα2 (200U/mL) or left untreated, transfected with the indicated siRNAs pools and
1017 subjected to Western blotting analysis with antibodies against the indicated proteins. Data are means ±
1018 SD of three independent experiments, *p<0.05, **p<0.01,***p<0.001, paired t-tests.

1019

1020 **Figure 6. Effect of reduced expression of MTA2 on the replication of YFV, WNV, VSV and MeV-**
1021 **GFP.** Huh-7 cells were transfected with the indicated siRNAs pool, treated or not with IFNα2
1022 (200U/mL) for 24 hours and infected with WNV (A) or YFV (B) for 24 hours, at the MOIs indicted in
1023 the MM section. The percentages of the cells positive for viral protein Env was determined by flow
1024 cytometric analysis. HMC3 cells were transfected with the indicated siRNAs pool, treated or not with
1025 IFNα2 (200U/mL) for 24 hours and infected with VSV for 18 hours (C) or MeV-GFP for 24 hours (D),
1026 at the MOIs indicted in the MM section. The percentages of the cells positive for viral protein G or GFP
1027 were determined by flow cytometric analysis. Data are expressed relatively to the siRNA NT control of
1028 each experiment. Data are means ± SD of three or four independent experiments, *p<0.05,
1029 **p<0.01,***p<0.001, paired t-tests.

1030

1031 **Supplementary figure legends**

1032

1033 **Figure S1. Quality control and reproducibility of the screens.** (A) HMC3 cells were transfected with
1034 either pool of 3 siRNAs against IFNAR or IFITM3 or non-targeting (NT) siRNAs, treated with IFNα2
1035 (1000U/mL) for 24 hours and infected with ZIKV PF13 at a MOI of 7 PFU/cell for 24 hours. The
1036 number of cells positive for viral protein E was assessed by confocal analysis using the pan-flavivirus
1037 anti-E antibody 4G2. (B) Distribution of the "number of cells per 3 fields" parameter for each screen.
1038 The values of the control wells (cells transfected with siRNA targeting KIF11) are shown in dark gray.
1039 (C) Representation of the number of cells per 3 fields of screen 1 as a function of the screen 2. The green
1040 line represents the linear regression as compared to the expected perfect correlation (dotted black line).
1041 (D) Distribution of the "percentage of infected cells" parameter for each screen in the first analysis. The
1042 values of the control conditions (cells transfected with siRNAs targeting IFNAR1 or IFNAR2) are
1043 shown in dark grey. (E) Representation of the percentage of infected cells per well of screen 1 as a
1044 function of screen 2, as identified by the first analysis. The green line represents the linear regression as
1045 compared to the expected perfect correlation (dotted black line). (F) Representation of the percentage
1046 of infected cells per well in the analysis 1 as a function of analysis 2. The green line represents the linear
1047 regression. (G) HMC3 cells were transfected with pools of 3 siRNAs targeting the indicated genes or

1048 with non-targeting (NT) control siRNAs. The relative abundances of the mRNAs of the candidate genes
1049 were determined by RT-qPCR analysis and were normalized with respect to GAPDH mRNA level.
1050 They are expressed relatively to abundance in cells transfected with NT siRNAs set at 1. Data are means
1051 ± SD of three or four independent experiments. ND: not determined due to mRNA levels below assay
1052 threshold. The samples are the same than in Fig. 1E-H.
1053
1054 **Figure S2. Efficacy of the specific siRNAs.** Huh-7.5 cells (A) or A549-ACE2 cells (B) were transfected
1055 with pool of 3 siRNAs targeting the indicated genes or with non-targeting (NT) control siRNAs. The
1056 relative abundances of the mRNAs of the candidate genes were determined by RT-qPCR analysis and
1057 were normalized with respect to GAPDH mRNA level. Values are expressed relatively to abundance in
1058 cells transfected with NT siRNA in each experiment, set at 1. Data are means ± SD of three or four
1059 independent experiments. ND: not determined due to mRNA levels below assay threshold. The samples
1060 are the same than in Fig. 2.
1061
1062 **Figure S3. Localization of GFP-tagged version of APOL1 and APOL3 in HMC3 cells**. Cells were
1063 transfected with GFP-tagged versions of APOL1 and APOL3. Thirty hours later, they were stained with
1064 antibodies recognizing EEA1 or CD63 and with NucBlue to detect nuclei. Images are representative of
1065 numerous observations over 2 independent experiments.


A
Transfection of individual siRNA
Interferon treatment
ZIKV PF13
D1
D2
D3
Immunofluorescence assay (Env positive cells)
Antiviral gene
Control
Proviral gene
B
IFNAR
Antiviral genes
Proviral genes
Zscore Screen 2
Zscore Screen 1
C
Zscore Screen 2
Zscore Screen 1
D
Antiviral effect
IRF9 IFITM3 MTA2 PXK GPD2 C1R XCL1 NMI IFI16
Proviral effect
LY6E USP18 ISG15 APOL3 GBP3 NAPA NADK ISG20 IRF2 CCND3 C22orf39 RUBCN
E
ZIKV GE/ µg tot. RNA
NT +IFN
NT -IFN
IFNAR1
IRF9
IFITM3
MTA2
PXK
GPD2
NMI
IFI16
+ IFN
F
Ratio of infected cells (log2)
G
ZIKV GE/ µg tot. RNA
LY6E
USP18
ISG15
APOL3
NAPA
ISG20
IRF2
CCND3
H
Ratio of infected cells (log2)


A
HCV GE/µg tot. RNA
NT +IFN
NT -IFN
IFNAR1
IRF9
IFITM3
MTA2
GPD2
+ IFN
B
TCID50/ml
NT +IFN
NT -IFN
IFNAR1
IRF9
IFITM3
MTA2
GPD2
+ IFN
C
HCV GE/µg tot. RNA
NT +IFN
NT -IFN
USP18
ISG15
GBP3
NAPA
+ IFN
D
TCID50/ml
NT +IFN
NT -IFN
USP18
ISG15
GBP3
NAPA
+ IFN
E
SARS-CoV-2 GE/µg total RNA
NT
NT -IFN
IFNAR1
IRF9
IFITM3
MTA2
GPD2
+ IFN
F
% spike positive cells
NT
NT -IFN
IFNAR1
IRF9
IFITM3
MTA2
GPD2
+ IFN
G
SARS-CoV-2 GE/µg total RNA
NT
NT -IFN
LY6E
USP18
ISG15
APOL3
NAPA
+ IFN
H
% spike positive cells
NT
NT -IFN
LY6E
USP18
ISG15
APOL3
NAPA
+ IFN


HMC3
Podocytes
A
B
C
D
E
F
G
H
I
APOL1
APOL3
copies/µg total RNA
- IFN
+ IFN
Expression level of targeted genes
si NT
si APOL1
si APOL3
si USP18
Ratio of infected cells
si NT ni
NS5
ENV
actin
DENV-2
WNV
VSV
MeV-GFP
MVA-GFP


A
merge
zoom
APOL1-GFP
GM130
GFP-APOL3
GM130
B
merge
zoom
APOL1-GFP
PI4KB
GFP-APOL3
PI4KB
C
DMSO
10nM
40nM
160nM
PI(4)P
D
Ratio of infected cells
1.5
1.0
0.5
0.0
**
*
*
CVB3
WNV
ZIKV
-IFN
ZIKV
+IFN
DMSO
10 nM
40 nM
160 nM


HMC3
Huh7
A
B
C
D
E
F
G
H
relative mRNA levels
si NT
si MTA2
si IFNAR1
- IFN
+ IFN
- IFN + ZIKV
+ IFN + ZIKV
ZIKV GE/ µg tot. RNA
% infected cells

I
si NT non infected
si NT
si MTA2
si IFNAR1
MTA2
NS5
Env
Actin
- IFN
+ IFN

J
si NT non infected
si NT
si MTA2
si IFNAR1
MTA2
NS5
Env
Actin
- IFN
+ IFN


A
WNV
% infected cells
25
20
15
10
5
0
***
- IFN
+ IFN
B
YFV
% infected cells
20
15
10
5
0
**
si NT
si MTA2
- IFN
+ IFN
C
VSV
Ratio of infected cells
1.2
1.0
0.8
0.6
0.4
0.2
0.0
*
- IFN
+ IFN
D
MeV-GFP
Ratio of infected cells
1.2
1.0
0.8
0.6
0.4
0.2
0.0
*
*
si NT
si MTA2
- IFN
+ IFN